 SAN DIEGO, Jan. 20, 2021 GLOBE NEWSWIRE -- Adamis Pharmaceuticals Corporation NASDAQ: ADMP Adamis announced today the submission of an Investigational New Drug IND to FDA for the investigational use of Tempol for the treatment of Coronavirus COVID-19. The submission of the IND to FDA followed a Pre-IND meeting with FDA in which FDA gave specific recommendations on Chemistry, Manufacturing and Controls CMC and Clinical aspects to be included in the IND. The Company plans to seek government andor non-government funding to study the treatment and prevention of COVID-19 with Tempol. 